2 assets in Urethra Neoplasm

Therapeutic assets addressing Urethra Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Urethra Neoplasm	National Cancer Institute (NCI)	P2	B (57)
Nivolumab Urethra Neoplasm	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)